Nature's Products acquires Nutrition 21 businesses
This article was originally published in The Tan Sheet
Executive Summary
Contract manufacturer and consumer health products packager Nature's Products acquires Nutrition 21's Iceland Health vitamin brand and its store-brand business for $3.2 million. Purchase, N.Y.-based Nutrition 21 signed a letter of intent in November, saying it would divest certain assets because the firm's revenues had suffered in the first quarter of 2010 (1"The Tan Sheet" Nov. 9, 2009). Nutrition 21 said it will retain its "profitable ingredients business and its patent portfolio." Nature's Products of Sunrise, Fla., noted Dec. 30 that Iceland Health is "a leading brand in the direct response and mass market channels" focused on omega-3s and joint-care and will complement the firm's diversification strategy. The acquisition also will provide synergies in materials and operations areas, and will streamline the supply chain. Nature's Products plans to enhance its nutritional product offerings, strengthen and develop marketing campaigns and secure new leadership
You may also be interested in...
People In Brief
Former FDA commissioner Hayes dies: Arthur Hull Hayes Jr., who led FDA from April 1981 through September 1983 and was a nationally known professor of clinical pharmacology, died on Feb. 11, 2010, from complications caused by a chronic illness, according to an obituary published by Munson-Lovetere Funeral Homes. He was 76. After being appointed FDA commissioner by President Ronald Reagan, Hayes' directed FDA's response to the Tylenol tampering in 1982, called for a voluntary moratorium on direct-to-consumer advertising of prescription medicines and weathered criticism on the FDA's approval of the sweetener aspartame. He earned a Rhodes Scholar degree in philosophy, politics and economics in 1957 before studying medicine, serving in Army Medical Corps from 1965-1967 and teaching medicine and pharmacy at Cornell and Pennsylvania State University before moving to FDA, and later was provost and dean at New York Medical College. According to FDA's Web site, in 1986 Hayes shifted to executive positions in the pharmaceutical industry, served on the editorial boards of Clinical Pharmacology and Therapeutics, Rational Drug Therapy and the Journal of Clinical Pharmacology, and was president of the American Society of Clinical Pharmacology and Therapeutics and the U.S. Pharmacopoeia. He retired in 2005, five years after founding MediScience Associates consultants, part of Nelson Communications Inc
Sales & Earnings In Brief
Santarus expects OTC Zegerid in 2010: The proton pump inhibitor's originator expects Merck/Schering-Plough to launch OTC Zegerid, should FDA approve it, in the first half of 2010. FDA's action date on the Zegerid switch application is set for December (1"The Tan Sheet" June 29, 2009, In Brief). In its Nov. 4 earnings release, San Diego-based Santarus raised its fiscal 2009 revenue guidance to $150 million from $145 million, but expects challenging quarters ahead due to changes in the PPI market, including this month's planned launch of Novartis' OTC Prevacid 24HR. Santarus increased product-related revenues 29.8 percent to $38.3 million in the third quarter. Rx Zegerid sales grew 12.1 percent to $31.5 million
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”